Coherus Oncology announced promising interim clinical data for tagmokitug, an investigational antibody, in treating esophageal squamous cell carcinoma (ESCC). In frontline ESCC patients, tagmokitug combined with toripalimab and chemotherapy achieved a confirmed overall response rate (cORR) of 75%, rising to 89% after additional data. The treatment showed durable benefits in second-line ESCC and manageable safety, supporting further development. Coherus plans to expand patient enrollment and continue evaluating tagmokitug's effectiveness across multiple cancer types.
Coherus Oncology's interim clinical data on tagmokitug in esophageal cancer provides context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 03:21 WIB: out of 150 priced US health-sector stocks, 103 rose and 46 fell today. Notable movers include TDOC (Teladoc Health Inc) up 17.05% at USD 7.55 with a typical hold time of 39 days, SLS (SELLAS Life Sciences Group Inc.) down 14.71% at USD 10.38 with a 7-day hold, and CLPT (ClearPoint Neuro Inc) up 9.08% at USD 10.57 with balanced buy/sell activity and an 11-day hold.
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
The global dermatological therapeutics market is projected to grow from about $43 billion in 2025 to $97 billion by 2034, with a compound annual growth rate of around 10%. This growth is fueled by increasing cases of acne, psoriasis, and other chroni...
Blockchain.com has launched TRX options trading, providing easier access to TRON's native token through its platform. This move expands the TRON ecosystem's reach by simplifying options trading for retail and institutional users worldwide. TRON, know...
